Clinical Trials Browser

Phase 3 × INDUSTRY × farletuzumab × Clear all

NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Phase 3 Terminated

1,100 enrolled 30 charts

Ovarian Neoplasms